Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Skin health peptide research spans two mechanistic clusters: ECM remodeling and dermal angiogenesis (GHK-Cu, BPC-157), and cellular repair with regenerative signaling (TB-500, Epitalon). Three of the four peptides are on the July 23–24, 2026 FDA PCAC advisory docket. This guide covers mechanisms, evidence quality, and COA verification — not dosing or medical advice.
2026 FDA PCAC Advisory Update
BPC-157, TB-500, and Epitalon are on the FDA Pharmacy Compounding Advisory Committee (PCAC) advisory docket for July 23–24, 2026. These peptides were either removed from FDA Category 2 in April 2026 or nominated via a separate pathway. The PCAC reviews and recommends — it does not authorize compounding. Any final FDA rule would follow later. Full regulatory detail →
| Peptide | Skin Mechanism | Target Application | MW / Format | 2026 Regulatory |
|---|---|---|---|---|
| GHK-Cu | TGF-β collagen upregulation | ECM remodeling | ~1,227 Da (Cu complex) | Removed from Cat-1 |
| BPC-157 | VEGF angiogenesis | Dermal microvasculature | ~1,419 Da | PCAC July 2026 |
| TB-500 | G-actin sequestration | Re-epithelialization | ~4,964 Da | PCAC July 2026 |
| Epitalon | Telomerase activation in somatic cells | Fibroblast replicative lifespan | ~390 Da | PCAC docket |
The first mechanistic cluster acts on the extracellular matrix directly: GHK-Cu through gene-level modulation of collagen synthesis and matrix metalloproteinase activity; BPC-157 through angiogenic signaling that rebuilds the dermal microvasculature supplying nutrients and oxygen to fibroblasts and keratinocytes.
Tripeptide–copper complex · ~1,227 Da · topical and injectable research use
GHK-Cu (glycyl-L-histidyl-L-lysine copper[II]) is a naturally occurring tripeptide first isolated from human plasma albumin by Loren Pickart in the 1970s. Its copper-chelating structure gives it a unique ability to modulate gene expression at scale: Pickart et al. (2015, Journal of Aging Science) demonstrated that GHK-Cu regulates more than 2,000 human genes in dermal fibroblasts, primarily through activation of TGF-β1 signaling. The practical result is a net pro-collagen, anti-collagenase environment.
Collagen Synthesis
Activates TGF-β1 in fibroblasts → upregulates COL1A1 / COL1A2 (type I collagen). Gorouhi & Maibach (2009) documented consistent collagen and glycosaminoglycan increases across cell culture models.
MMP Inhibition
Downregulates MMP-2 and MMP-9 (collagenases that degrade existing ECM), creating a dual pro-ECM effect: more collagen synthesized + less degraded. Leyden et al. (1990 Skin Pharmacology) showed increased dermal density in a double-blind clinical trial.
Regulatory note:GHK-Cu has a distinct regulatory history — it was previously on the FDA's Category 1 (503A compounding-permitted) list and was removed from that list. It is not on the July 2026 PCAC advisory docket. Topical cosmetic use faces no regulatory barrier; injectable use is under research-chemical terms.
Pentadecapeptide · ~1,419 Da · injectable research peptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from human gastric juice by the Sikiric group. In skin, its primary lever is vascular: BPC-157 upregulates VEGF-A in fibroblasts and endothelial cells, driving formation of new capillaries in the dermis. These new vessels supply the oxygen and growth factors needed for fibroblast collagen production and keratinocyte proliferation — making angiogenesis the upstream bottleneck BPC-157 removes.
Angiogenic Pathway
VEGF-A upregulation → endothelial proliferation → dermal microvasculature. eNOS/NO activation provides vasodilatory tone in new vessels. Sikiric et al. (2012, Current Pharmaceutical Design) reviewed 83 published studies covering vascular, GI, and musculoskeletal healing contexts.
Fibroblast Activation
FAK-paxillin pathway activation drives fibroblast migration toward wound sites and accelerates granulation tissue formation. Novaes et al. (2019 Nutrients) reviewed BPC-157 in wound healing and GI mucosa repair — noting distinct angiogenic and anti-inflammatory mechanisms.
The second cluster acts at the cellular level: TB-500 drives the physical re-epithelialization process by promoting keratinocyte migration via actin dynamics; Epitalon targets the molecular clock of skin cell aging through telomerase activation and epigenetic reprogramming.
Thymosin Beta-4 · 43 aa · ~4,964 Da · injectable research peptide
TB-500 is a 43-amino-acid G-actin sequestering peptide whose role in skin focuses on the mechanical process of wound closure: epithelial cells must migrate across the wound surface (re-epithelialization) before any other repair phase can complete. Malinda et al. (1997, FASEB Journal) demonstrated that thymosin β4 dramatically accelerated corneal epithelial cell migration in vitro and wound healing in vivo — the first evidence that TB-500's actin-sequestering activity specifically drove epithelial motility.
LKKTETQ Active Fragment
The LKKTETQ heptapeptide motif within thymosin β4 promotes leading-edge actin polymerization and lamellipodia extension in migrating keratinocytes (Harding 2002, J Cell Sci). Smart et al. (2010, J Investigative Dermatology) confirmed that topical Tβ4 increased keratinocyte migration and wound closure rates in full-thickness skin wound models.
Matrix Attachment Signaling
Beyond keratinocyte migration, TB-500 increases ILK (integrin-linked kinase) and PINCH-1 expression — matrix attachment and cell survival proteins required for fibroblast anchorage during granulation tissue remodeling. Crockford (2007, Ann NYAS) reviewed clinical development of Tβ4 in dermal wounds, noting favorable effects on dermal fibrosis.
Ala-Glu-Asp-Gly tetrapeptide · ~390 Da · injectable research peptide
Epitalon is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its anti-aging mechanism in skin is molecular: Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) demonstrated that Epitalon activates telomerase in human somatic cells and lengthens telomeres in human embryonic fibroblasts. Dermal fibroblasts from aged skin exhibit shortened telomeres and reduced replicative capacity — a documented contributor to skin thinning and reduced wound healing in older adults.
Telomerase Reactivation
Epitalon activates hTERT (telomerase reverse transcriptase), which is epigenetically silenced in most adult somatic cells. This extends the replicative lifespan of skin fibroblasts and may restore their capacity to produce collagen and respond to growth factor signals. Key caveat: published data comes primarily from the Khavinson group; independent replication in skin fibroblasts is limited.
Circadian & Oxidative Protection
Anisimov et al. (St. Petersburg group) showed Epitalon normalizes melatonin secretion in aged subjects — restoring circadian amplitude. Melatonin directly reduces lipid peroxidation in skin cells, lowering oxidative DNA damage during the dark-phase DNA repair window. This circadian-protective mechanism is distinct from the telomerase pathway.
Previously on FDA Category 1 (503A compounding-permitted) list; removed from that list. Not on PCAC docket. Standard grey-market research chemical status.
Regulatory detailRemoved from FDA Category 2 in April 2026. Not authorized for compounding — gray zone pending PCAC review.
Regulatory detailRemoved from FDA Category 2 in April 2026. Not authorized for compounding — gray zone pending PCAC review.
Regulatory detailOn the PCAC July 23–24, 2026 advisory docket. Not among the April 2026 Cat-2 removals — nominated for compounding review from a different pathway.
Regulatory detailThe four peptides in this guide have widely different molecular weights and structural complexity — verification requirements vary accordingly.
GHK-Cu is a metal complex, not a simple peptide. The COA should report both the tripeptide MW (~340 Da) and the copper complex MW (~1,227 Da), plus copper content by weight (~5.1%). Vendors reporting only the peptide MW may not be testing the full chelated compound. ICP (inductively coupled plasma) metal analysis confirms copper incorporation. HPLC purity ≥98% for the tripeptide component.
BPC-157 (~1,419 Da, 15 aa) is well-characterized: HPLC purity ≥98% and LC-MS molecular weight confirmation are the standard checks. The peptide sequence (GEPPPGKPADDAGLV) is unambiguous. HPLC retention time should be consistent across vendors using the same method.
TB-500 at ~4,964 Da is one of the heaviest peptides in this guide. HPLC purity alone is insufficient for a 43-amino-acid peptide — LC-MS/MS sequence confirmation is strongly preferred. Endotoxin testing (LAL or rFC) is critical for a peptide this size produced by SPPS, as endotoxin co-purification risk increases with chain length and synthesis complexity.
Epitalon at ~390 Da is small and relatively straightforward to verify: HPLC purity ≥99% and LC-MS MW confirmation. For small peptides produced in bacterial systems, endotoxin testing (LAL assay) is critical — LPS fragments can co-purify with peptides under 1 kDa. Solid-phase synthesis (SPPS) is preferred over recombinant production for tetrapeptides of this size.
Browse the COA database → Disclosed Labs tracks public COA data across vendors for all four peptides. Janoshik and Vanguard have the highest COA coverage in the database for peptides in this guide.
Skin health peptide research encompasses two mechanistic clusters. The first targets extracellular matrix (ECM) remodeling and dermal angiogenesis: GHK-Cu is a copper-binding tripeptide that modulates over 2,000 human genes, primarily through upregulation of TGF-β–driven collagen I synthesis and downregulation of MMP-2/MMP-9 (collagenases); BPC-157 is a synthetic pentadecapeptide that drives VEGF-mediated dermal angiogenesis and fibroblast proliferation via the FAK-paxillin pathway. The second cluster targets cellular repair and regeneration at a deeper level: TB-500 (Thymosin Beta-4) promotes keratinocyte migration along wound edges via G-actin sequestration and the LKKTETQ active-fragment's documented role in epithelial re-epithelialization; Epitalon (Epithalon) is a synthetic tetrapeptide studied for telomerase activation in human somatic cells and reversal of DNA methylation age markers in skin fibroblasts. Three of these four peptides — BPC-157, TB-500, and Epitalon — are on the FDA Pharmacy Compounding Advisory Committee (PCAC) advisory docket for July 23–24, 2026. GHK-Cu has a distinct regulatory history: it was previously on the Category 1 (503A compounding-permitted) list and was removed from that list. None are FDA-approved for any cosmetic or dermatological indication.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma albumin by Loren Pickart in the 1970s. Its molecular weight is approximately 340 Da as the tripeptide and ~1,227 Da as the copper complex. Its biological activity is unusually broad: Pickart et al. (2015, Journal of Aging Science) demonstrated that GHK-Cu modulates the expression of over 2,000 human genes when applied to fibroblasts — roughly 10% of the entire human genome — with the predominant effect being upregulation of genes involved in ECM production and tissue repair. The primary pro-collagen mechanism involves TGF-β (transforming growth factor beta) pathway activation: GHK-Cu binds cell surface receptors and upregulates TGF-β1 signaling in dermal fibroblasts, which drives increased transcription of COL1A1 and COL1A2 (type I collagen), the dominant structural collagens in skin. Simultaneously, GHK-Cu downregulates MMP-2 and MMP-9 (matrix metalloproteinases that degrade existing collagen), creating a net pro-ECM environment. Gorouhi and Maibach (2009, International Journal of Dermatology) reviewed GHK-Cu's dermatological evidence base across wound healing, anti-aging, and photoaged skin contexts, noting consistent increases in collagen and glycosaminoglycan production in fibroblast cell culture models. Leyden et al. (1990, Skin Pharmacology) showed that topical GHK-Cu formulations increased dermal density in a double-blind clinical trial against control. Important distinction: GHK-Cu is used both as a topical cosmetic ingredient (Neova, certain retinol serums) and as an injectable research chemical — mechanisms differ slightly by route. Regulatory note: GHK-Cu was previously on the FDA's Category 1 (503A compounding-permitted) list and was removed from that list; it is not currently on the PCAC advisory docket.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (~1,419 Da) isolated by the Sikiric group from human gastric juice. Its skin-relevant mechanisms operate through three converging pathways. Primary: VEGF upregulation — BPC-157 consistently upregulates vascular endothelial growth factor A (VEGF-A) in fibroblasts and endothelial cells, driving therapeutic angiogenesis in wounded or damaged skin. New capillary networks supply oxygen and growth factors critical to the proliferative phase of wound healing; the resulting oxygen gradient drives keratinocyte migration and fibroblast collagen production. Secondary: FAK-paxillin pathway activation — BPC-157 stimulates focal adhesion kinase (FAK) and its scaffold protein paxillin, promoting fibroblast migration toward the wound site and accelerating formation of granulation tissue. This pathway is independent of IGF-1 or growth hormone receptor signaling, which distinguishes BPC-157 mechanistically from GH-secretagogue peptides. Third: NF-κB and COX-2 transcriptional suppression — BPC-157 reduces pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) in the acute wound inflammatory phase, shortening the inflammatory period and accelerating transition to the proliferative phase. Sikiric et al. (2012, Current Pharmaceutical Design) reviewed BPC-157 across 83 published studies covering GI, musculoskeletal, and vascular healing contexts. Novaes et al. (2019, Nutrients) reviewed BPC-157's wound-healing evidence across skin and GI mucosa. BPC-157 was removed from FDA Category 2 in April 2026 and is on the PCAC July 23–24, 2026 advisory docket.
TB-500 (Thymosin Beta-4, Tβ4) is a 43-amino-acid G-actin sequestering peptide (~4,964 Da) whose primary cellular mechanism — actin filament regulation — is directly relevant to the wound healing process in skin. Re-epithelialization (coverage of wound surface by new keratinocytes) is the rate-limiting step in wound closure for most partial-thickness wounds. Malinda et al. (1997 FASEB Journal) demonstrated that thymosin β4 dramatically accelerated corneal epithelial cell migration in vitro and accelerated corneal wound healing in vivo — the first evidence that Tβ4's actin-sequestering activity was specifically driving epithelial cell motility. Harding et al. (2002, Journal of Cell Science) showed that Tβ4's cellular function in motility was mediated by its LKKTETQ active fragment, which promotes leading-edge actin polymerization and lamellipodia extension in migrating cells. In skin specifically: Smart et al. (2010, Journal of Investigative Dermatology) demonstrated that topical thymosin β4 increased keratinocyte migration and skin wound closure in full-thickness wound models. Crockford (2007, Annals of the New York Academy of Sciences) reviewed the clinical development of TB-500 for dermal wounds, noting favorable dermal fibrosis reduction alongside wound closure. Beyond keratinocyte migration, Tβ4 also increases integrin-linked kinase (ILK) and PINCH-1 expression — proteins that mediate matrix attachment and cell survival during tissue regeneration. TB-500 was removed from FDA Category 2 in April 2026 and is on the PCAC July 23–24, 2026 advisory docket.
Epitalon (Epithalon, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide (~390 Da) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its anti-aging mechanism in skin operates primarily through two pathways. Telomerase activation: Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) demonstrated that Epitalon activates telomerase in human somatic cells and lengthens telomeres in human embryonic fibroblasts — a finding that places it in a category distinct from all other peptides in this guide. Telomere attrition is a recognized molecular mechanism of cellular aging; dermal fibroblasts from aged skin show shortened telomeres and reduced replicative capacity compared to young skin. Epitalon's proposed mechanism is through reactivation of telomerase reverse transcriptase (hTERT), which is epigenetically silenced in most adult somatic cells. The second pathway is epigenetic/circadian: Anisimov et al. (St. Petersburg group; multiple publications in gerontology journals) showed that Epitalon normalizes melatonin secretion from the pineal gland in aged animals, restoring circadian amplitude — which in turn regulates skin DNA repair cycling (the dark-phase DNA repair window that declines with age). Additionally, Reiter et al. and other groups have documented that melatonin directly reduces lipid peroxidation in skin cells, reducing oxidative DNA damage. Khavinson's broader work (summarized in Peptides in Aging, Karger 2010) characterizes Epitalon as part of a class of 'bioregulatory peptides' that restore epigenetic programs in differentiated tissues. Important caveat: the telomerase activation data is predominantly from the Khavinson group with limited independent replication. Epitalon is on the PCAC July 23–24, 2026 advisory docket (not among the April 2026 Cat-2 removals — nominated via a different pathway).
The distinction is primarily bioavailability and molecular target depth. Topical cosmetic peptides (Matrixyl/palmitoyl pentapeptide-4, Argireline/acetyl hexapeptide-3, Syn-Coll/palmitoyl tripeptide-5, GHK-Cu in creams) are formulated to penetrate the stratum corneum and signal to superficial dermal fibroblasts. The skin barrier limits penetration depth: most topical peptides reach the dermis to 0.3–2 mm below the surface at best, and efficacy depends heavily on formulation chemistry (penetration enhancers, pH, vehicle hydrophilicity). GHK-Cu is effective both topically (for collagen signaling in accessible fibroblasts) and as an injectable (for systemic delivery to deeper tissue). Injectable research peptides — BPC-157, TB-500, Epitalon — achieve systemic distribution, reaching dermal tissue from the vascular side. This matters for angiogenesis (BPC-157's VEGF upregulation requires endothelial cells to receive the signal from the blood side) and for keratinocyte migration signals (TB-500 as a systemic G-actin reservoir). The tradeoff: topical cosmetics are accessible, low-risk, and studied in clinical cosmetic trials. Injectable research peptides have mechanistic depth and broader tissue access but carry regulatory uncertainty and require sterile technique. COA verification is mandatory for injectables — purity, absence of endotoxin, correct MW — which is the primary use case for Disclosed Labs' database.
COA (Certificate of Analysis) verification for skin peptides surfaces several compound-specific quality signals. GHK-Cu is a metal complex, not a simple peptide: its molecular weight (the copper chelate is ~1,227 Da vs the free tripeptide ~340 Da) and metal content (copper weight percent ~5.1%) should appear on the COA. Labs that only report the peptide MW without the copper complex or don't include ICP (inductively coupled plasma) metal analysis may not be testing the actual GHK-Cu compound — they may be testing GHK (the free tripeptide). BPC-157 (~1,419 Da) should be verified by HPLC purity ≥98% and LC-MS molecular weight confirmation. The 15-amino-acid sequence is well-established enough that any reputable lab can confirm it. TB-500 at ~4,964 Da is one of the heavier peptides in this category and is more technically challenging to verify: HPLC purity alone is insufficient for a molecule this large — LC-MS/MS is strongly preferred to confirm the intact 43-amino-acid sequence. Epitalon at ~390 Da is small and relatively easy to verify by HPLC purity ≥99% and LC-MS. The small size means endotoxin testing (LAL or rFC) is especially important if the peptide is produced in bacterial expression systems (E. coli) rather than solid-phase peptide synthesis (SPPS) — endotoxin contamination is a more significant risk for smaller peptides that can co-purify with LPS fragments. Disclosed Labs tracks COA count by lab for these peptides; Janoshik and Vanguard have the highest overall COA coverage in the database.
Regulatory status for all four peptides is evolving and varies by application type. GHK-Cu: as a cosmetic ingredient in topical formulations, GHK-Cu is commercially sold with no regulatory barrier (it appears in many commercial skincare products). As an injectable research chemical, it is sold under research-only terms. Its regulatory status is unique: GHK-Cu was previously listed on the FDA's Category 1 (503A compounding-permitted) list and has since been removed from that list — meaning licensed compounding pharmacies may no longer compound it for patient use. BPC-157: removed from FDA Category 2 in April 2026, pending the PCAC advisory review on July 23–24, 2026. It is currently available as a research chemical but may not be compounded by licensed pharmacies. TB-500: same status as BPC-157 — April 2026 Cat-2 removal, on PCAC July 2026 docket. Epitalon: on the PCAC July 2026 advisory docket via a different pathway (not among the 12 April 2026 Cat-2 removals). None are FDA-approved for any skin health indication. All are sold as research chemicals in the United States. The PCAC advisory meeting will result in recommendations to the FDA; any final rule would come 6–18 months later. Check our FDA regulatory alert page for the latest status updates.
Disclosed Labs